A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 Days

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

GSK573719

7 day repeat dose

Trial Locations (7)

RG2 0TG

GSK Investigational Site, Reading

PR7 7NA

GSK Investigational Site, Buckshaw Village, Chorley

L22 0LG

GSK Investigational Site, Waterloo, Liverpool

G81 2DR

GSK Investigational Site, Clydebank, Glasgow

B15 2SQ

GSK Investigational Site, Edgbaston, Birmingham

CF14 5GJ

GSK Investigational Site, Llanishen

M15 6SX

GSK Investigational Site, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY